I also wonder about the lesser severity of the new

I also wonder about the lesser severity of the new Omicron and how it might change our trial efficacy. Not for the bad but for the good. Will they say (FDA) that although Leronlimab is now working at better than 82% like your last trial indicated. We see a lesser variant responsible for these added improvements in your trial. Then tell us we need to have a documented split use trial on both or more variants. Anything to delay us further. I hate to believe this shit but it seems plausible to have this pushed on us for more extensive trials needed because of variants changing. Like will we ever see the light at the end of the tunnel. Let’s hope that this doesn’t happen.